AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

RCKT · NASDAQ · Biotechnology

Rocket Pharmaceuticals (RCKT)

Develops gene therapies for rare immune and cardiovascular disorders.

$3.43

After-hours close+0.08 (+2.24%)

At close$3.36(+2.60%)

RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Zacks Investment ResearchSep 16
Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking AlphaSep 15
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Seeking AlphaSep 15
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
GuruFocusSep 15
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
Business WireSep 15
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
Zacks Investment ResearchSep 9Market move
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of “Hold” by Analysts
Defense WorldAug 21Price target
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
Zacks Investment ResearchAug 11
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Business WireAug 10
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
GuruFocusAug 3
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
Business WireAug 3
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Business WireJun 12
Rocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking AlphaJun 9
Rocket Pharmaceuticals, Inc. (RCKT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking AlphaJun 5
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Business WireMay 28
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Zacks Investment ResearchMay 11
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
Zacks Investment ResearchMar 30
Rocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 Transcript
Seeking AlphaMar 27
Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI
Proactive InvestorsMar 27
Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder
ReutersMar 27